People

Gilead CEO Milligan capped a rocky year — and his career — with the new #1 compensation package in the big leagues of biopharma

Gilead’s recently departed CEO John Milligan capped a year marked by setbacks, a major write-off and big questions about the company's future under a new helmsman with what currently stands as the biggest pay package of all the major league CEOs in biopharma.


Image: John Milligan speaks to Bloomberg in 2014 Bloomberg

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 45,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->